Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Neutrophil Extracellular Traps & Their Role in Autoimmunity

Kathy Holliman  |  Issue: May 2018  |  May 18, 2018

Certain medications associated with drug-induced autoimmunity were previously shown to trigger NET formation and to impair NET degradation. The thyroid medication propylthiouracil, linked to drug-induced AAV, can induce NET formation and impair NET degradation.2 Also, cocaine that has been contaminated with levamisole, an antihelmintic drug, can induce NETs, doing so through cholinergic receptors, Dr. Grayson says.3

For this study, researchers examined the effect of four medications causally linked to drug-induced autoimmunity—procainamide, hydralazine, minocycline and clozapine—on NET formation, NET degradation and NET protein content. The rationale of the research was to demonstrate that some drugs linked with drug-induced autoimmunity enhance NET formation. These findings could then potentially provide evidence that neutrophils and NETs “are involved in the pathogenesis of specific drug-induced and idiopathic autoimmune diseases,” according to the published report.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In the study, neutrophils were first isolated from heparinized blood, and then the neutrophils were treated with the four drugs. After four hours of stimulation, procainamide and hydralazine induced significant NET formation, whereas the NET formation induced by clozapine and minocycline was not significant.

“This provides some indirect evidence that neutrophils are implicated in drug-induced autoimmunity and that the drugs may trigger NETs as a potential inciting event in why these patients develop autoantibodies,” Dr. Grayson says. “One of the hallmarks of drug-induced autoimmunity is that these patients usually develop multiple different antibodies, so the same patient can make an antibody seen in lupus and ANCA vasculitis at the same time.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The research also provides new information about the signaling pathways by which the drugs trigger NETs. According to Dr. Grayson, hydralazine triggers NETs by altering intracellular calcium levels in neutrophils. Procainamide, which is no longer used in clinical practice, triggers NETs by binding to cholinergic receptors on the surface of neutrophils. “That suggests that there is crosstalk between neutrophils, or innate immune cells, and the autonomic nervous system transmitters.”

The results indicate the class of drugs that could potentially triggers NETs. “We would predict that drugs that basically bind and modulate cholinergic receptors would be more likely to trigger NETs, and similarly, drugs that modulate intracellular calcium levels could also potentially trigger NETs,” Dr. Grayson says. The onset of autoimmunity by a hydralazine or similar drug will not necessarily occur when the patient first starts taking it. In fact, it can happen months or years later, he says.

Drug-Induced Autoimmunity: A Disease Model

Drug-induced autoimmunity is providing an “excellent disease model to further understand idiopathic disease,” according to an editorial published with the research report.4 “Additional exploration and characterization of drug-induced NETosis and the auto­antigen ‘cargo’ carried within released NETs will help us better understand autoimmune mechanisms,” Amr H. Sawalha, MD, at the University of Michigan, Ann Arbor, wrote in his editorial.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsDrug Updates Tagged with:neutrophil extracellular traps

Related Articles

    Rheumatology Researchers Explore Role of Neutrophils in Autoimmunity

    January 19, 2016

    SAN FRANCISCO—To unravel the mysteries of how autoimmunity begins in the body and, one day, to interrupt that process, rheumatology researchers are exploring the role of neutrophils, especially when they form and release neutrophil extracellular traps (NETs). At a panel discussion on Nov. 6, 2015, held at the American College of Rheumatology’s Basic Research Conference,…

    Case Report: Hydralazine-Induced ANCA-Associated Vasculitis

    February 16, 2021

    Hydralazine has been in use as a treatment for hypertension, most notably in heart failure patients, since 1951.1 The drug is a known cause of autoimmune disease, most specifically hydralazine-induced lupus.  Hydralazine-induced lupus occurs in 7–13% of those taking the medication.2-4 It often presents with constitutional symptoms, arthritis/arthralgias, cutaneous lesions, sero­sitis, myalgias and/or hepatomegaly. Features…

    Rheum After 5: Introducing Dr. Grayson & the Affordable Rock ‘n’ Roll Act

    January 19, 2021

    Peter Grayson, MD, MSc, a tenure track investigator at the National Institutes of Health (NIH) Intramural Research Program, Bethesda, Md., sometimes wonders how his life would have turned out if the band he was playing in during college had signed a recording contract with a major record label. Dr. Grayson has been playing the piano…

    The Granulomatosis of Wegener’s

    May 16, 2011

    Delving deeper into the nonvasculitis aspects of the disease

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences